Zeto Announces Winners of Clinical Trial Sponsorship Program

News provided by

Jun 25, 2024, 08:07 ET

SANTA CLARA, Calif., June 25, 2024 /PRNewswire/ -- Zeto, Inc., an award-winning medical technology firm, is proud to announce the winners of its 2024 Clinical Trial Sponsorship program. This initiative, announced at the 2023 Society for Neuroscience Convention in Washington D.C., invited research teams to submit proposals for clinical trials using the Zeto EEG device platform. The program aims to support advanced clinical research and to bring innovative applications closer to real-world implementation.

Zeto Announces Winners of 2024 Clinical Trial Sponsorship Program.

An expert jury panel, composed of professionals from the fields of neurology and neuroscience research, carefully reviewed all submissions and selected the winners based on several factors, including alignment with Zeto's mission to enhance patient care through innovative EEG applications.

"The winners of the 2024 Clinical Trial Sponsorship program are conducting groundbreaking research aimed at improving patient care. These projects align perfectly with Zeto's mission, and we are proud to support them. We look forward to continuing this sponsorship program annually," said Florian Strelzyk, Chief Sales Officer at Zeto.

The winners of the 2024 Clinical Trial Sponsorship program are:

Efficacy of Portable EEG Technology in Pre-hospital Triage of Large Vessel Occlusion Strokes by Liqi Shu, MD and a multidisciplinary team from Brown University and Rhode Island Hospital, USA

This clinical trial will evaluate the Zeto EEG system's ability to enhance pre-hospital triage of large vessel occlusion (LVO) strokes, aiming to significantly improve diagnostic speed and accuracy. By integrating Zeto's advanced, portable EEG technology into EMS protocols, the study seeks to ensure rapid and appropriate routing of stroke patients to specialized care facilities, thereby optimizing treatment times and patient outcomes.

Gaze-independent visual brain computer interface for use by patients with limited to no eye control by Marc M. Van Hulle, Ph.D ., and Arne Van Den Kerchove, Ph.D . from KU Leuven, Belgium

Brain computer interfaces (BCIs) have been serving paralyzed individuals by decoding their brain activity directly. A popular paradigm requires the patient to gaze at displayed targets but this is challenging for patients with limited to no eye control. Prof. Hulle's team has developed a gaze-independent paradigm and EEG decoder that copes with this issue, which will be tested on patients using the Zeto EEG headset.

The Far-North Remote Online Zeto Electroencephalography (F.R.O.Z.E.) Trial by Marcus C. Ng, MD from University of Manitoba, Canada

The FROZE Trial will use Zeto EEG in an emergency room in the far north of the Canadian Arctic for use by everyday clinicians backed by remote interpretation by board-certified epileptologists. This trial will determine how effectively the Zeto platform could improve patient care in even the remotest regions of the Earth.

"We are happy to support the winners of the Clinical Trial Sponsorship program and to see the advantages of Zeto's dry EEG headset in action. Its ease of use, comfort, and ability to bring EEG out of the lab and into the medical research environment provide significant benefits to researchers in projects such as these," said A. Mark Mento, Director of Enterprise Sales at Zeto.

Zeto will provide each clinical trial with its FDA cleared products, including up to two headsets per trial along with electrode supplies for up to 100 patients, accompanied by on-site training and ongoing product support. Trials are set to start before the end of 2024 with an anticipated duration ranging between 6 to 12 months.

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology firm, is at the forefront of advancing EEG brain monitoring and diagnostics for healthcare.
Zeto's revolutionary FDA-cleared EEG platform brings the traditional EEG procedure to the 21st century by offering a zero-prep, wireless, easy-to-wear, portable headsets with active, dry electrodes that can be positioned as per the 10-20 system.
The company plans to leverage its platform technology to improve access and quality to medical EEG testing and to enable and improve adjacent biomedical research and clinical trials.

To learn more about Zeto's products, please visit https://zeto-inc.com or email us at [email protected].

SOURCE Zeto, Inc.